Paper published in a journal (Scientific congresses and symposiums)
Bolero-6:Phase 2 Study of Everolimus plus Exemestane versus Everolimus or Capecitabine Monotherapy in HR+HER2- Advanced Breast Cancer
Ejlerstsen, Bent; JERUSALEM, Guy; Hurvitz, Sara et al.
2013In Journal of Clinical Oncology, 31, p. 660
Peer Reviewed verified by ORBi
 

Files


Full Text
ASCO - Bolero 6 poster.pdf
Publisher postprint (1.37 MB)
Request a copy
Annexes
BOLERO-6 - Phase II study of everolimus plus exemestane versus everolimus ... - abstract.pdf
Publisher postprint (696.93 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Oncology
Author, co-author :
Ejlerstsen, Bent;  Copenhagen University Hospital
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Hurvitz, Sara;  UCLA Medical Center, Los Angeles
de Boer, Richard;  Royal Melbourne Hospital, Melbourne
Taran, Tetiana;  Novartis Pharmaceuticals Corporation, New Jersey
Sahmoud, Tarek;  Novartis Pharmaceuticals Corporation, New Jersey
Burris, Howard;  Sarah Cannon Research Institute, Nashville
Language :
English
Title :
Bolero-6:Phase 2 Study of Everolimus plus Exemestane versus Everolimus or Capecitabine Monotherapy in HR+HER2- Advanced Breast Cancer
Publication date :
2013
Event name :
American Society of Clinical Oncology
Event organizer :
American Society of Clinical Oncology
Event place :
Chicago, United States
Event date :
du 31 mai 2013 au 04 juin 2013
Audience :
International
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
Volume :
31
Pages :
abstract TPS660
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 17 September 2013

Statistics


Number of views
130 (9 by ULiège)
Number of downloads
3 (3 by ULiège)

Bibliography


Similar publications



Contact ORBi